TS
Therapeutic Areas
Novoron Bioscience Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Proteinopathies Program | Neurodegenerative diseases (e.g., Alzheimer's, Parkinson's) via prion-like protein spread | Preclinical |
| Neuroregeneration Program | Acute Traumatic Spinal Cord Injury | Preclinical |
Leadership Team at Novoron Bioscience
SG
Shawn Gahr, MIA
COO & Co-founder, Board Director
DW
David Weiner, MD
Executive Chairman, Board Director
WH
William Hoekstra, PhD
Drug Discovery & Development
SB
Sarah Busch, PhD
Non-Clinical Translation
RM
Ryan McMillian, MBA
CFO & Financial Strategy